How many insider trades does FilingIQ track for BIIB?

FilingIQ tracks 901 Form 4 insider transactions for BIIB (BIOGEN INC.), covering filings from Feb 12, 2015 onwards. 6 of those were filed in the last 90 days.

Are BIIB insiders net buyers or net sellers?

Across the full Form 4 history for BIIB, 20 transactions (2%) were open-market purchases and 66 (7%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.

Where does BIIB insider data come from?

Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.

What sector is BIIB in?

BIOGEN INC. (BIIB) is classified in the Healthcare sector, specifically Drug Manufacturers - General, with a current market capitalisation of $29.03B.

BIIB insider trading

NasdaqGS Healthcare

BIOGEN INC. — scored insider trade history from SEC Form 4 filings, parsed and contextualised by FilingIQ.

Total Form 4 trades

901

Last 90 days

Buys / sells

2% / 7%

Market cap

$29.03B

About BIOGEN INC.

Biogen Inc. discovers, develops, manufactures, and delivers therapies in the United States, Europe, Germany, Asia, and internationally. The company provides TECFIDERA, VUMERITY, AVONEX, PLEGRIDY, and TYSABRI for multiple sclerosis (MS); SPINRAZA for spinal muscular atrophy; SKYCLARYS to treat Friedreich's Ataxia; QALSODY for treating amyotrophic lateral sclerosis; FUMADERM to treat plaque psoriasis; BENEPALI, an etanercept biosimilar referencing ENBREL; IMRALDI, an adalimumab biosimilar referencing HUMIRA; FLIXABI, an infliximab biosimilar referencing REMICADE. It offers LEQEMBI for the treatment of Alzheimer's disease; ZURZUVAE for the treatment of postpartum depression; RITUXAN to treat non-Hodgkin's lymphoma, chronic lymphocytic leukemia (CLL), rheumatoid arthritis, two forms of ANCA-associated vasculitis, and pemphigus vulgaris; RITUXAN HYCELA for non-Hodgkin's lymphoma and CLL; GAZYVA to treat CLL and follicular lymphoma; OCREVUS for relapsing MS and primary progressive MS; LUNSUMIO to treat relapsed or refractory follicular lymphoma; glofitamab for aRelapsed or refractory diffuse large B-cell lymphoma; and other anti-CD20 therapies. Biogen Inc. has collaboration and license agreements with Merz Therapeutics; Alkermes Pharma Ireland Limited; Denali Therapeutics Inc.; UCB; Eisai Co., Ltd.; Genentech, Inc.; Neurimmune SubOne AG; Ionis Pharmaceuticals, Inc.; Samsung Bioepis; and Sage Therapeutics, Inc., as well as collaborations with Stoke Therapeutics, Inc. for the development and commercialization of zorevunersen, a disease modifying medicine for the treatment of Dravet syndrome; Dayra Therapeutics, Inc. to develop oral macrocyclic peptides; Vanqua Bio, Inc. for developing Vanqua's preclinical oral C5aR1 antagonist compound; City Therapeutics, Inc. to develop select novel RNAi therapies. The company was founded in 1978 and is headquartered in Cambridge, Massachusetts.

Company website: www.biogen.com

BIIB insider activity at a glance

FilingIQ has scored 901 insider transactions for BIIB since Feb 12, 2015. The most recent filing in our index is dated May 1, 2026.

Across the full history, 20 open-market purchases and 66 open-market sales were filed under transaction codes P and S respectively. Compensatory share awards (code A) and option exercises (code M) are tracked separately and not counted here.

The average FilingIQ composite score on BIIB insider trades is 55.8/100, produced by FilingIQ's multi-factor Form 4 model. Model framework documented at methodology.

View live BIIB trades on FilingIQ Raw filings on SEC EDGAR

Other Healthcare tickers with recent insider activity

UTHR 1,098

UNITED THERAPEUTICS Corp

APLS 279

Apellis Pharmaceuticals, Inc.

KMDA 218

KAMADA LTD

BMY 185

BRISTOL MYERS SQUIBB CO

ADPT 184

Adaptive Biotechnologies Corp

GH 169

Guardant Health, Inc.

ISRG 166

INTUITIVE SURGICAL INC

VTRS 165

Viatris Inc

13F funds holding BIIB

SECTOR GAMMA AS

$19.40M · 4.4% of AUM

Arlington Partners LLC

$3.32M · 1.6% of AUM

Politicians who have traded BIIB

Whitfield, Ed

U.S. Rep. , KY · 107 trades

Frequently asked

How many insider trades does FilingIQ track for BIIB?: FilingIQ tracks 901 Form 4 insider transactions for BIIB (BIOGEN INC.), covering filings from Feb 12, 2015 onwards. 6 of those were filed in the last 90 days.
Are BIIB insiders net buyers or net sellers?: Across the full Form 4 history for BIIB, 20 transactions (2%) were open-market purchases and 66 (7%) were open-market sales. Compensatory awards and option exercises are filtered out of these counts.
Where does BIIB insider data come from?: Every transaction shown on this page is sourced directly from SEC EDGAR Form 4 filings. FilingIQ parses the raw XML, normalises insider identity across reporting variations, and scores each trade on its multi-factor composite model.
What sector is BIIB in?: BIOGEN INC. (BIIB) is classified in the Healthcare sector, specifically Drug Manufacturers - General, with a current market capitalisation of $29.03B.

Methodology & sources

Every BIIB insider transaction shown on FilingIQ is parsed directly from a public SEC Form 4 XML filing. Insider identity is normalised across reporting variants (CIK changes, name spellings, related-party indirect holdings). The FilingIQ composite score is documented in full on the team page and algo disclosure. Not investment advice; see disclaimer.